FHTX (Foghorn Therapeutics) Unearned Income

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FHTX Foghorn Therapeutics Inc FHTX
70 GF Score
Price $4.80
GF Value $5.26
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Foghorn Therapeutics Unearned Income?

Unearned Income only applies to banks.

FHTX
70GF Score
Foghorn Therapeutics Inc FHTX
Unearned Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Foghorn Therapeutics (FHTX) Overvalued in 2026?

Based on GuruFocus' analysis, Foghorn Therapeutics stock appears to be undervalued. The current stock price of $4.80 is trading 8.7% below its estimated GF Value™ of $5.26. GuruFocus considers Foghorn Therapeutics to be Fairly Valued.

Key valuation signals for FHTX:

  • Unearned Income:
  • GF Value™: $5.26 vs. price of $4.80 (8.7% below fair value)
  • GF Score™: 70/100 with 5 warning signs

No single metric tells the full story. See the FHTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Foghorn Therapeutics Business Description

Address 99 Coolidge Avenue, Suite 500, Watertown, MA, USA, 02472
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.
70GF Score

Get the complete analysis for FHTX

Unearned Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.80
Price
$5.26
GF Value